EU MDR vs UK MHRA vs US FDA: What Global Medical Device Companies Should Prioritise First 

For a Medical Device company that wants to expand globally, the biggest question arises is of market prioritization. Entering a market is both a regulatory challenge and a strategic decision. The three largest regulated Medical Device markets outside Asia are— the United States, the European Union, and the United Kingdom — each have their own regulatory framework, timelines, costs, and market access implications. Getting the sequencing right can accelerate your global launch; while a one wrong decision can lead to rework, cost overruns, and delayed revenue. 

This article provides a comparative analysis of the three frameworks — US FDA, EU MDR, and UK MHRA — and offers a practical prioritisation framework for companies navigating their global regulatory strategy. 

Overview of the Three Frameworks 

US FDA: The 510(k) and PMA Pathways  

Any market entering the US market must comply with the regulations laid by USFDA. Understanding the different pathways is vital for timely approvals.  

The US Food and Drug Administration (FDA) regulates medical devices under a risk-based classification system.  

Table 1

The primary market approval pathways are: 

1. 510(k) Premarket Notification: For Class II Devices that can demonstrate substantial equivalence to a legally marketed predicate device in US. Typically the fastest and most cost-effective US pathway for established device types. 

2. Premarket Approval (PMA): Required for Class III high-risk devices. A full safety and effectiveness demonstration is required, typically including clinical trial data. Significantly more time and resource-intensive than 510(k). 

3. De Novo Classification: For novel low-to-moderate risk devices with no predicate, providing a pathway to Class II classification. 

EU MDR: The CE Marking Pathway 

The EU Medical Device Regulation (EU MDR 2017/745), which replaced the previous Medical Device Directive, introduced significantly more rigorous requirements for CE marking — the mandatory conformity marking for Medical Devices sold in the European Economic Area. Key features: 

4. Risk-based classification:  

EU MDR (Regulation (EU) 2017/745) Medical Device Classification 

Under the EU Medical Device Regulation (MDR) 2017/745, Medical Devices are classified according to their intended purpose and inherent risks into four classes: 

Table 2

Class I Subcategories 

Table 3

5. Notified Body involvement: Required for all Class I Devices with a measuring function or supplied sterile, and for all Class IIa, IIb, and III devices 

6. Clinical Evidence requirements: EU MDR raised the bar for clinical evaluation significantly — clinical investigation data may now be required for device types previously approved on equivalence grounds 

7. EUDAMED: The European database for Medical Devices, with increasing transparency and post-market surveillance reporting obligations 

UK MHRA: Post-Brexit Regulatory Independence 

Following Brexit, the UK Medicines and Healthcare products Regulatory Agency (MHRA) now operates an independent Medical Device regulatory framework. Key developments: 

In Great Britain (England, Scotland, and Wales), the MHRA (Medicines and Healthcare products Regulatory Agency) uses a classification system that is largely based on the former EU Medical Devices Directives and is aligned with risk-based principles similar to the EU framework. 

Table 4

Class I Subcategories 

Table 5

8. UK Conformity Assessed (UKCA) marking is required for devices placed on the UK market — CE marking from the EU is no longer recognised for new market authorisations in Great Britain 

9. The MHRA has introduced a phased transition, with ongoing updates to timelines for UKCA recognition 

10. The UK has announced its intention to implement a reformed device regulatory framework broadly aligned with, but not identical to, EU MDR 

11. Northern Ireland operates under a separate regime — EU MDR continues to apply for devices sold in Northern Ireland under the Windsor Framework 

Side-by-Side Comparison 

Table 6

Prioritisation Framework: Which Market First? 

The right sequencing depends on your device type, clinical data situation, target markets, and business model. The following framework captures the most common strategic scenarios: 

Scenario 1: US FDA First 

Recommended when: 

12. Your device has a clear, well-established predicate for 510(k) — fast and relatively cost-effective when a suitable predicate exists, with strong international credibility among regulators, distributors, and investors.  

13. Your primary commercial target is the US market or US-based distributors and hospital systems 

14. You have strong pre-clinical and bench testing data but limited clinical investigation data — 510(k) often does not require clinical trials 

15. You are planning to use FDA clearance as the reference for India CDSCO MD-14 application — FDA is one of India’s most recognised reference authorities 

Scenario 2: EU MDR First 

Recommended when: 

16. Your device lacks a suitable U.S. predicate, making the FDA pathway more complex (e.g., De Novo or PMA), while the EU MDR route may offer a more commercially attractive first-market strategy depending on available clinical evidence and Notified Body access 

17. Your primary commercial targets are European distributors or hospital systems 

18. You have robust clinical evaluation data that meets EU MDR’s elevated requirements 

19. Your global regulatory strategy treats CE marking as the anchor for multi-market expansion —  

20. CE marking is commonly used as supporting regulatory evidence in many jurisdictions, although it does not automatically grant market access.  

Scenario 3: India Parallel with US or EU 

Recommended when: 

21. India is a significant commercial priority — either for market size, local manufacturing advantage, or as a strategic anchor for SAARC and emerging market expansion 

22. Your device addresses an Indian health system priority (cardiovascular, orthopaedics, diagnostics, diabetes care) where market potential justifies parallel regulatory investment 

23. You have an Authorised Agent and regulatory partner in India already in place — minimising the marginal cost of running India in parallel 

For companies planning to enter India, one of the most important regulatory strategy decisions is which reference-jurisdiction approval to pursue first. For MD-14 import licence applications, CDSCO recognises regulatory approvals or Free Sale Certificates from the United States, European Union, United Kingdom, Canada, Australia and Japan as important regulatory supporting evidence. Obtaining approval in one of these jurisdictions before filing in India can significantly facilitate the CDSCO review process and strengthen the overall submission package.  

Common Mistakes in Global Regulatory Sequencing 

24. Pursuing all three markets simultaneously without adequate regulatory resources, leading to delays in all three 

25. Treating the UK as equivalent to EU post-Brexit — UKCA and CE are now separate requirements with different timelines 

26. Underestimating EU MDR clinical evidence requirements for Class IIb and III devices — companies that assumed equivalence-based CE marking would continue to apply have faced significant delays 

27. Failing to plan for India regulatory filing during the primary market approval process — Indian registration requires many of the same documents, and preparing them in parallel is far more efficient than revisiting them later 

Conclusion 

There is no universally correct answer to the question of which global regulatory market to prioritise first. The optimal sequence depends on the device classification, intended use, available clinical evidence, target markets, commercial objectives, and internal regulatory resources. 

Successful MedTech companies typically define their global regulatory strategy early, align clinical and quality activities with the requirements of multiple jurisdictions, and use their first major regulatory approval—whether FDA clearance, CE marking, or another recognised approval—as a foundation for expansion into additional markets. For companies considering India, early planning is particularly valuable because many of the technical, clinical, quality, and regulatory documents required by CDSCO can be prepared in parallel with submissions to other major regulators, improving efficiency and reducing time to market.